bluebird bio (BLUE) said Tuesday that it is launching a restructuring plan to reduce its workforce by 25%.
The company said the layoffs and other measures will bring it to quarterly cash flow break-even in H2 of next year and reduce cash operating expenses by 20% in Q3 of next year.
Chief Executive Andrew Obenshain said the restructuring will help the gene therapy company attract more investment.
Price: 0.5062, Change: +0.02, Percent Change: +3.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。